# Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

> **NCT00413218** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 450 (actual)

## Conditions studied

- Candidiasis, Invasive
- Candidemia
- Mycoses

## Interventions

- **DRUG:** Isavuconazole
- **DRUG:** Caspofungin
- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT00413218
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-08
- **Primary completion:** 2015-03-03
- **Final completion:** 2015-03-03
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00413218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00413218, "Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00413218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*